How to buy Citius Pharmaceuticals stock (CTXR)

Citius Pharmaceuticals is a biotechnology business based in the US. Citius Pharmaceuticals shares (CTXR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.68 – an increase of 41.54% over the previous week. Citius Pharmaceuticals employs 22 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Citius Pharmaceuticals stock

Buy Citius Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Citius Pharmaceuticals stock price (NASDAQ: CTXR)

Use our graph to track the performance of CTXR stocks over time.

Citius Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-22.

Latest market close	$3.68
52-week range	$2.44 - $26.75
50-day moving average more info button	$0.45
200-day moving average more info button	$0.66
Wall St. target price	$4.67
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.24

Is it a good time to buy Citius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Citius Pharmaceuticals price performance over time

Historical closes compared with the close of $3.31 from 2024-12-26

1 week (2024-12-20)	27.31%
1 month (2024-11-29)	-0.30%
3 months (2024-09-27)	534.22%
6 months (2024-06-28)	467.07%

1 year (2023-12-28)	328.92%
2 years (2022-12-28)	-83.14%
3 years (2021-12-28)	38.25
5 years (2019-12-27)	27

Citius Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-24.74%
Return on equity TTM	-41.49%
Profit margin	0%
Book value	$0.47
Market Capitalization more info button	$87.1 million

TTM: trailing 12 months

Citius Pharmaceuticals share dividends

We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months.

Have Citius Pharmaceuticals's shares ever split?

Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.

Citius Pharmaceuticals share price volatility

Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $2.44 up to $26.75. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.663. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Citius Pharmaceuticals overview

Citius Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey. .

Frequently asked questions

null
What percentage of Citius Pharmaceuticals is owned by insiders or institutions?
Currently 6.81% of Citius Pharmaceuticals shares are held by insiders and 17.029% by institutions. How many people work for Citius Pharmaceuticals?
Latest data suggests 22 work at Citius Pharmaceuticals. When does the fiscal year end for Citius Pharmaceuticals?
Citius Pharmaceuticals's fiscal year ends in September. Where is Citius Pharmaceuticals based?
Citius Pharmaceuticals's address is: 11 Commerce Drive, Cranford, NJ, United States, 07016 What is Citius Pharmaceuticals's ISIN number?
Citius Pharmaceuticals's international securities identification number is: US17322U2078 What is Citius Pharmaceuticals's CUSIP number?
Citius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 17322U207